Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.

Ereshefsky L, Davis CM, Harrington CA, Jann MW, Browning JL, Saklad SR, Burch NR.

J Clin Psychopharmacol. 1984 Jun;4(3):138-42.

PMID:
6736273
2.

Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.

Chang WH, Shieh YS, Liu HC, Jann MW, Chien CP.

Eur Neuropsychopharmacol. 1994 Jun;4(2):119-26.

PMID:
7919941
3.

Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol.

Lane HY, Lin HN, Hu OY, Chen CC, Jann MW, Chang WH.

Prog Neuropsychopharmacol Biol Psychiatry. 1997 Feb;21(2):299-311.

PMID:
9061775
4.

Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.

Lane HY, Chang WH, Chang YC, Hu OY, Lin HN, Jann MW, Hu WH.

Psychiatry Res. 1997 Sep 19;72(2):127-32.

PMID:
9335203
5.

Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.

Huang HF, Jann MW, Tseng YT, Chung MC, Chien CP, Chang WH.

Psychiatry Res. 1995 Jul 28;57(2):101-8.

PMID:
7480377
6.

Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.

Chang WH, Jann MW, Chiang TS, Lin HN, Hu WH, Chien CP.

Neuropsychobiology. 1996;33(1):12-6.

PMID:
8821369
7.

[Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].

Dutoit D, Thomas P, Leroux JM, Vaiga G, Pommery J, Cottencin O, Erb F, Goudemand M.

Encephale. 1995 Nov-Dec;21(6):417-24. French.

PMID:
8674466
8.

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.

J Psychiatry Neurosci. 1994 Jul;19(4):254-64. Review.

9.

Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM.

Psychopharmacology (Berl). 1986;90(4):468-70.

PMID:
3101102
10.

Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.

Ulrich S, Neuhof S, Braun V, Meyer FP.

Int Clin Psychopharmacol. 1999 Jul;14(4):219-28.

PMID:
10468314
11.
12.

Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.

Louza Neto MR, Müller-Spahn F, Rüther E, Scherer J.

Pharmacopsychiatry. 1988 Sep;21(5):226-31.

PMID:
3227054
13.

Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.

McKane JP, Robinson AD, Wiles DH, McCreadie RG, Stirling GS.

Br J Psychiatry. 1987 Sep;151:333-6.

PMID:
3322467
14.

Dose-dependent reduced haloperidol/haloperidol ratios in schizophrenic patients.

Chang WH, Hwu HG, Lane HY, Lin SK, Chen TY, Chen H, Wei HL, Lin WL, Lin HN.

Psychiatry Res. 1991 Sep;38(3):215-25.

PMID:
1754634
15.

Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.

Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S, Otani K.

Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):575-8.

PMID:
11999910
16.

Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder.

Volavka J, Cooper TB, Czobor P, Meisner M.

Arch Gen Psychiatry. 1995 Oct;52(10):837-45.

PMID:
7575103
18.

Haloperidol plasma 'threshold' levels for relapse prevention in schizophrenia: a study with haloperidol decanoate.

Altamura AC, Tacchini GL, Maes M.

Eur Neuropsychopharmacol. 1995;5 Suppl:55-8.

PMID:
8775759
19.

Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia.

Kelly MW, Perry PJ, Coryell WH, Miller DD, Arndt SV.

Psychopharmacology (Berl). 1990;102(4):514-20.

PMID:
2096408
20.

Determination of haloperidol and reduced haloperidol in the plasma and blood of patients on depot haloperidol.

Eyles DW, Whiteford HA, Stedman TJ, Pond SM.

Psychopharmacology (Berl). 1992;106(2):268-74.

PMID:
1549652
Items per page

Supplemental Content

Support Center